Abstract
Background Giardia intestinalis is a protozoal parasite infecting the gastrointestinal tract worldwide. Chronic infections/reinfections are common, with adverse nutritional consequences for critical growth during the first five years of life. Vitamin B12 (cobalamin) is absorbed primarily in the ileum of the small intestine, where Giardia trophozoites attach and replicate. Bacteria activate bioavailable vitamin B12, which is essential for human DNA synthesis and development. A disturbance in cobalamin biosynthesis caused by giardiasis may contribute to impairment of childhood development and growth.
Methodology/Principal Findings We performed a longitudinal analysis on 61 Ecuadorian children using multi-parallel real-time quantitative PCR and whole genome sequencing. Children had increased Giardia DNA burden from ages 3 to 5 (p = 0.0012) and 7.58 times more frequent Giardia infections (1.31 to 34.33, P = 0.0176). There was an increased alpha diversity/ Giardia fg/µl in three-year-olds compared to age-matched non-infected (30.20 vs 4.37, p = 0.050), but decreased alpha diversity/ Giardia fg/µl in five-year-olds compared to age-matched non-infected children (0.21 vs 4.31, p = 0.021). Alpha diversity/ Giardia fg/µl was also decreased in samples collected longitudinally from the same children at five compared to 3 years (p = 0.031). Cobalt transport protein (CbiN) (FDR < 0.003) and IPR011822 (Cobalamin-dependent methionine synthase) sequences were decreased in infected children (p < 0.002) and among those with greatest Giardia burdens (p < 0.001).
Conclusion/Significance Giardia intestinalis infection may affect bacterial diversity in the ileum where vitamin B12 is activated, as suggested by a reduced proportion of Cobalt transport protein component (CbiN) gene sequences in the gut microbiome of infected children. These findings are potentially important to our understanding of how Giardia infections may affect childhood growth.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Informed written consent was obtained from a parent or guardian of each child. The study protocols were approved by the Bioethics Committee of the Universidad Internacional De Ecuador, Quito, Ecuador. From the parent study, the results of stool microscopy were given to the parent/guardian and anti-parasite treatment was provided where appropriate. The study was also approved by the Baylor College of Medicine, institutional review board H-33219.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data supporting the conclusions of this article will be available in the NCBI BioProject repository upon acceptance.
